MarketInOut Stock Screener Log In | Sign Up
 

Kailera Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Kailera Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,621.19 mln
Float56.71 mln
Earnings Date06/01/2027

Relative Strength

95 / 100
Top performer

Debt / Equity

0.01
Debt-free

ROE

-22.66
Deeply negative

ROA

-20.71
Deeply negative

Business Description

Kailera Therapeutics is a clinical-stage company founded in 2024 and headquartered in Waltham, Massachusetts, focused on developing treatments for obesity and related metabolic conditions. Its pipeline includes both injectable and oral drug candidates at various stages of development, spanning small molecules and peptides. The company holds exclusive rights to develop and sell four metabolic disease treatments worldwide, excluding Greater China.

Key Fundamentals

EPS-4.51
ROE-22.66
ROIC-105
ROA-20.71
EBITDA, mln-190
EV / EBITDA-2.94
EV / EBIT-2.93

Quote Details

Last 12.85
Change -0.42 (-3.17%)
Open 13.18
Volume 1,560,071
Turnover 20,046,912
Average Volume 1,375,758

Financial Ratios

Leverage Ratio1.08
Current Ratio11.11
Price / Book1.31
Price / Tangible Book1.31
Debt / Equity0.01

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 14.22% 97 / 100   
1 Month 7.26% 91 / 100   
2 Months -28.25% 17 / 100   
6 Months -42.81% 15 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog